about
microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinomaIdentification and validation of oncogenes in liver cancer using an integrative oncogenomic approachMutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvementTargeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptidesOncofetal gene SALL4 in aggressive hepatocellular carcinomaSp1 site is crucial for the mouse claudin-19 gene expression in the kidney cellsAcrosome-specific gene AEP1: identification, characterization and roles in spermatogenesisCharacterization of an acrosome protein VAD1.2/AEP2 which is differentially expressed in spermatogenesisGene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinomaPredictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limitingInhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.The embryotrophic activity of oviductal cell-derived complement C3b and iC3b, a novel function of complement protein in reproduction.Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values.Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma.Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma.A protein-based set of reference markers for liver tissues and hepatocellular carcinomaPredicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.Molecular biology of gastric carcinoma: from laboratory to bedside.Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression.Clinicopathologic and gene expression parameters predict liver cancer prognosis.MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis.An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancerDiscovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma.Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expressionTwo-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122.Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy.Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapyCytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stageCirculating mortalin autoantibody--a new serological marker of liver cirrhosis.Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinomaAXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.Applicability of tissue aspirate for quick parathyroid hormone assay to confirm parathyroid tissue identity during parathyroidectomy for primary hyperparathyroidism.Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma.Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation.
P50
Q24595141-EB70CA23-3F4F-431A-A0FC-D5ECBA494B80Q24633776-4FAE3B2F-321F-425B-9EF4-04F8E254EB21Q24672137-F3B33F16-FDEB-4578-85DC-CB3B92EC0ABDQ27696166-14E6128A-C8DC-4594-8E28-4AAA33F17CBCQ28292533-D8072AC5-D07C-4CAA-891A-DF422A1A128DQ28504768-545645B1-4972-4EAA-A79D-5C165CA22880Q28567236-05AD4B4F-E358-40E4-9FA9-592EE4B2364EQ28580279-318ED7AE-8ABF-43CA-9566-D8B49B9B1B16Q28740309-D2C9DA4E-23CD-44ED-ADD6-90FB1934A46FQ28742950-49116466-3834-4B56-9E18-2B91A1037D80Q30576918-81F8AC5D-56D2-4C93-8D79-1FE0DFB7164CQ30747633-9FED97D7-BCB5-4AA7-963E-A31108EF3E22Q33231146-67C157DA-49DA-4EE9-B934-C2A8EA42FFCDQ33287108-F9BFA694-E45A-40AD-B04A-F008872086BBQ33298434-32FB8D08-F691-4CFC-B876-F4DC3AEF464BQ33302500-D6FB3E50-33FE-4127-BDE5-4D2E04F99FAAQ33329606-80817614-56E2-44A1-BCFD-02121408BAE5Q33401908-6220A14F-A22A-4520-B63B-3A6593073C5AQ33499552-6C7A0992-951A-4112-88DE-29C49FEE3E7FQ33514753-13986485-B93F-4445-A9C0-63B2928D620FQ33547822-0E612609-07D4-4460-8327-CD69966B0C84Q33816796-036CDAC7-C85A-4E6C-963B-0CA9ED263EA0Q33961542-E6B0335B-052E-4593-93A4-F5AE5F80F7A2Q34070902-AF8AF34D-7ECD-45F6-A61C-22D87FABE078Q34103666-0E6F289C-B24F-4AA7-8AFC-C2C7543D2F72Q34324655-93CF51AB-4CEB-4FCE-AD15-ACEFBE4F4346Q34345765-F78433F1-C1BE-4F1A-8DA3-732ABE83DD83Q34383893-29DC010D-248D-414D-BF5A-7BD3A1017521Q34438689-E95803A5-D9B9-4F30-ABE6-25B132105D88Q34979073-EA6EC020-971B-4ADA-AE27-A99ACF106350Q35073177-D038A5F3-5126-4DFA-9833-6B40162D3BD4Q35092706-CF241405-EB61-4D57-807A-6A93C64226BBQ35627178-0B642A23-D376-4CB7-B088-A1DCFA1390FFQ35725150-9CA57BA0-D0E7-4B17-9A24-E42A6CCE6E5BQ35893965-8573C93E-9ECD-4BC5-A0F8-3385A92F18F6Q35899490-7929A4B6-9278-4786-82E2-2E902F6E0059Q36050864-94762892-D3B2-4218-8631-4A32CEF98612Q36420885-E2EBC4E6-41A7-4556-A544-C840A85B7012Q36478827-03F9E780-4731-4DA2-B008-E366B6C7C2CDQ36909491-F45A0442-DB68-470D-ADE1-5180B12CDAAE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John M. Luk
@ast
John M. Luk
@en
John M. Luk
@es
John M. Luk
@nl
John M. Luk
@sl
type
label
John M. Luk
@ast
John M. Luk
@en
John M. Luk
@es
John M. Luk
@nl
John M. Luk
@sl
altLabel
JM Luk
@en
prefLabel
John M. Luk
@ast
John M. Luk
@en
John M. Luk
@es
John M. Luk
@nl
John M. Luk
@sl
P1053
A-4085-2008
P106
P1153
7006777791
P1960
eBCssO0AAAAJ
P2013
P21
P31
P3829
P496
0000-0002-6323-7940